GLP-1 medication eligibility is based on your diagnosis, BMI, health risks and treatment goal. The FDA sources cited below include documents dated 2024 and 2026. For FDA-approved weight-management medications, adults usually qualify if they have:

  • A BMI of 30 or higher, or
  • A BMI of 27 or higher plus at least one weight-related condition, such as high blood pressure, type 2 diabetes, high cholesterol, cardiovascular disease or obstructive sleep apnea.

A licensed healthcare professional must decide whether a specific medication is appropriate. Meeting the FDA criteria does not guarantee a prescription or insurance coverage.

GLP-1 Qualification at a Glance

The medication and the reason for treatment both matter. Qualification for a weight-management drug follows a different path from qualification for a diabetes medication.

Your treatment goal Typical qualification Common medications
Weight loss or long-term weight management BMI 30 or higher, or BMI 27 or higher with a weight-related condition Wegovy, Zepbound, Saxenda
Type 2 diabetes treatment Diagnosed type 2 diabetes and a clinical need for improved blood sugar control Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus
Cardiovascular risk reduction Certain adults with established cardiovascular disease and overweight or obesity, or type 2 diabetes with cardiovascular risk Wegovy, Ozempic, Trulicity
Pediatric treatment Separate age, BMI percentile and diagnosis requirements apply Wegovy, Saxenda, Mounjaro and others

"GLP-1" refers to a group of medications, not one specific drug. Tirzepatide, the active ingredient in Mounjaro and Zepbound, activates both GIP and GLP-1 receptors.

Qualifying for a GLP-1 for Weight Loss

For FDA-approved weight-management medications, adults generally qualify through one of two paths.

BMI of 30 or Higher

A BMI of 30 or higher falls within the obesity range. A related medical condition is not required under the FDA criteria for weight-management treatment. Your clinician will still review your overall health, medications and treatment history.

If your BMI is between 27 and 29.9, you generally need at least one weight-related condition. Examples include:

  • High blood pressure
  • Type 2 diabetes
  • High cholesterol or dyslipidemia
  • Obstructive sleep apnea
  • Cardiovascular disease
  • Other health problems linked to excess weight

Wegovy and Zepbound are approved for chronic weight management alongside a reduced-calorie diet and increased physical activity.

BMI is a screening measure, not a complete diagnosis. A healthcare professional may also consider your waist circumference, weight history, medical conditions, medications, eating patterns and previous treatment attempts.

Qualifying for a GLP-1 for Type 2 Diabetes

A person with type 2 diabetes may qualify for a diabetes-approved GLP-1 medication when a healthcare professional believes it can improve blood sugar control or provide another approved benefit.

Examples include:

  • Ozempic, which contains semaglutide and is approved for adults with type 2 diabetes. Its FDA-approved indications also include certain cardiovascular and kidney-risk reductions in adults with type 2 diabetes.
  • Mounjaro, which contains tirzepatide and is approved with diet and exercise to improve blood sugar control in adults and certain children age 10 and older with type 2 diabetes.
  • Trulicity, Victoza and Rybelsus, which are other medications in the GLP-1 class.

Ozempic and Mounjaro are not FDA-approved solely as general-purpose weight-loss drugs. Wegovy and Zepbound are the corresponding FDA-approved products for chronic weight management when their criteria are met.

What a Healthcare Professional Will Check

During an evaluation, a clinician will usually review:

  1. Your height, weight and BMI
  2. Your weight-related diagnoses, such as hypertension, diabetes, high cholesterol or sleep apnea
  3. Your current medications, including insulin, sulfonylureas and over-the-counter products
  4. Your medical history, including pancreatitis, gallbladder disease, kidney disease, diabetic retinopathy and digestive problems
  5. Your pregnancy status or pregnancy plans
  6. Your family history of medullary thyroid carcinoma or MEN 2
  7. Your treatment goal, such as weight management, blood sugar control or cardiovascular risk reduction
  8. Your insurance requirements and ability to attend follow-up care

The FDA does not require every patient to complete a specific number of diets before receiving medication. An insurance company may still require prior authorization, medical records, proof of a qualifying BMI, documentation of related conditions or evidence of previous treatment.

Conditions That May Prevent or Delay Treatment

Some conditions and medications can rule out a specific GLP-1 product or require closer monitoring. Semaglutide and tirzepatide products are contraindicated in people with:

  • A personal or family history of medullary thyroid carcinoma
  • Multiple Endocrine Neoplasia syndrome type 2, also called MEN 2
  • A serious allergic reaction to the medication or one of its ingredients

A healthcare professional may also need to review severe gastrointestinal disease, a history of pancreatitis, gallbladder problems, diabetic retinopathy, kidney problems or the use of insulin and other medications that can cause low blood sugar. Mounjaro, for example, is not recommended for people with severe gastroparesis.

Weight-loss medications should not be used during pregnancy or when planning a pregnancy. Tell your healthcare professional if you are pregnant, breastfeeding or trying to conceive.

How to Start the Qualification Process

1. Calculate Your BMI

BMI is calculated using your weight and height:

BMI = weight in kilograms ÷ height in meters squared

A healthcare professional should confirm the result because BMI does not account for every factor that affects health or body composition.

2. Gather Your Medical Information

Prepare:

  • Recent weight measurements
  • A list of diagnoses
  • Current prescriptions and supplements
  • Recent blood sugar or A1C results, if applicable
  • Blood pressure and cholesterol information
  • Details about previous weight-management treatments
  • Your insurance information

3. Schedule an Evaluation

You can discuss GLP-1 treatment with a primary care clinician, endocrinologist, obesity-medicine specialist or qualified telehealth clinician. The clinician should assess your health rather than approve medication based only on a questionnaire.

4. Ask Your Insurer About Coverage

Ask whether your plan covers:

  • Weight-management medications
  • Diabetes medications
  • Wegovy, Zepbound, Ozempic or Mounjaro specifically
  • Prior authorization
  • Step therapy
  • Required documentation
  • Copay or deductible amounts

Insurance coverage for obesity treatment differs widely. Some plans cover GLP-1 medications for diabetes but exclude them for weight management.

What If Your BMI Is Below 27?

A BMI below 27 generally does not meet the FDA-approved adult criteria for chronic weight-management treatment with Wegovy or Zepbound. A clinician may still prescribe a medication for another FDA-approved condition, such as type 2 diabetes, when appropriate.

Using a GLP-1 medication only for cosmetic weight loss, without an approved medical indication, is not the standard FDA-approved use.

Be Cautious with Online and Compounded GLP-1 Products

Use a prescription from a licensed healthcare professional and obtain the medication through a state-licensed pharmacy. FDA-approved products have undergone review for safety, effectiveness and manufacturing quality.

Compounded semaglutide and tirzepatide products are not FDA-approved. The FDA has reported dosing errors, adverse events, fraudulent products and concerns about incorrect salt forms or confusing concentrations. The FDA recommends considering compounded drugs only when a patient's medical needs cannot be met by an available FDA-approved medication.

Be wary of any service that:

  • Prescribes medication without a real clinical evaluation
  • Does not require a prescription
  • Promises guaranteed weight loss
  • Offers "research use" injections
  • Does not identify the dispensing pharmacy
  • Provides unclear dosing instructions
  • Claims that a compounded product is the same as an FDA-approved drug

Bottom Line

Qualification is only the first step. Bring your BMI, diagnoses, medication list, recent lab results and insurance details to a licensed healthcare professional. That clinician can determine whether a specific medication fits your health needs, while your insurer determines whether the plan will pay for it.